Research & Clinical Studies | Diabetes and Endocrinology

research diabetes san diego

8851 Center Drive, Ste 212
La Mesa, CA 91942

619-466-4899

dmendo1@pacbell.net

Clinical research studies are crucial for the development of new medications and devices. They have provided breakthroughs in the treatment of endocrine diseases such as diabetes. We are proud to be contributors to studies that have passed the early stages regarding safety (Phase 1) and are now focused on the best effectiveness strategies for patients (Phases 2 and 3).

Diabetes and Endocrine Associates has conducted over 150 studies in the past 27 years, and our research has assisted in the development and approval of many of the important medications used by our patients every day.

People who participate in clinical studies have a special bond with us. We have a shared mission to improve care not only for ourselves but for others. Participants also typically receive study-related medical care and medication free of charge, and a stipend depending on the study. And most maintain long-term relationships with Denise and Lori

Below are clinical studies that are currently open and recruiting participants. Please click on the individual study for more information. However, this list changes continuously, and if you wish to be considered for these or any future studies please contact Denise and Lori anytime for a phone appointment or a visit to the office.

We hope you will join us.

  • Open Clinical Trials
  • Type 1 Diabetes
  • Comparing an investigational oral medication (vs. placebo) for people with type 1 diabetes currently on continuous insulin pump therapy or taking basal and mealtime insulin.
  • Comparing an investigational long-acting basal insulin vs. insulin glargine for people with type 1 diabetes currently taking Lantus and mealtime insulin.
  • Type 2 Diabetes
  • Comparing an approved weight loss medication (vs. placebo) for people with type 2 diabetes who have a history OR are at high risk for cardiovascular disease.
  • Comparing two (2) different, approved, long-acting basal insulins for people with type 2 diabetes who have a history OR are at high risk for cardiovascular disease.